Tyrosine Kinase Inhibitors: all 10,469 studies that test it

Page 64 of 105. Open to participants first (1,909), then studies with results posted, then the rest; newest registration first within each.

• A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Relapsing Multiple Sclerosis (RMS)Active, not recruitingNCT04586010Phase 3
• Fruquintinib and Raltitrexed Versus Fruquintinib Monotherapy in Advanced Colorectal CancerStatus unknownNCT04582981Phase 2
• Inflammatory Signal Inhibitors for COVID-19 (MATIS)CompletedNCT04581954Phase 1/2
• Clinical Study to Evaluate Pharmacokinetics and Safety of PF-06700841 After Single and Multiple Oral Doses as Modified Release FormulationsCompletedNCT04580797Phase 1
• A Study of REduction And DIscontinuation Treatment of TKI (Imatinib, Nilotinib, Dasatinib and Bosutinib)Status unknownNCT04578847Phase 2
• First-In-Human Phase I Trial of Ningetinib ( CT053PTSA ) in the Patients With Advanced Solid TumorsCompletedNCT04577703Phase 1
• A Study to Evaluate the Impact of Management Strategies on Gastrointestinal-Related Adverse Events in Participants With Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations Receiving TAK-788WithdrawnNCT04576208Phase 2
• A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule in Subjects With Advanced Endometrial CancerCompletedNCT04574284Phase 2
• Camrelizumab Combined With Apatinib Mesylate Tablets and Nab-paclitaxel in the Second-line Treatment of Advanced Gastric CancerStatus unknownNCT04572542Phase 1/2
• A Study of E7090 as Monotherapy and in Combination With Other Anticancer Agents in Participants With Estrogen Receptor Positive (ER+) and Human Epidermal Growth Receptor 2 Negative (HER2-) Recurrent/Metastatic Breast CancerCompletedNCT04572295Phase 1
• A Trial of SHR1258 in Patients With Biliary Tract CancerWithdrawnNCT04571710Phase 2
• Radiotherapy Combined With Irinotecan and Apatinib Followed by PD-1 Antibody and Apatinib for Advanced Solid TumorsStatus unknownNCT04569916Phase 2
• Anlotinib Combined With Dose-reduced Olaparib in Patients With Platinum-Sensitive Recurrent Ovarian CancerStatus unknownNCT04566952Phase 2
• Acalabrutinib With R-CHOP in Previously Untreated Mantle Cell LymphomaActive, not recruitingNCT04566887Phase 2
• A Study to Assess the Effect of Food Intake and Drug-drug Interactions of E7090 When Co-administered With Rabeprazole or Rifampin in Healthy ParticipantsCompletedNCT04565574Phase 1
• A Study in Healthy Subjects to Assess Bioavailability (Proportion of a Drug Which Enters the Circulation to Have an Active Effect) of Acalabrutinib Tablet and Protonpump Inhibitor Effect (Members of a Class of Medications That Inhibits in Gastric Acid Production) for RabeprazoleCompletedNCT04564040Phase 1
• Efficacy and Safety of 80mg Osimertinib in Patients With Non-small Cell Lung Cancer(NSCLC)CompletedNCT04563871Phase 2
• NPC - AXEL Study : Axitinib-AvelumabCompletedNCT04562441Phase 2
• Venetoclax-Obinutuzumab +/- Acalabrutinib in R/R CLLActive, not recruitingNCT04560322Phase 2
• TACE Combined With Camrelizumab and Apatinib in Intermediate and Advanced Hepatocelluar CarcinomaActive, not recruitingNCT04559607Not applicable
• Evaluationn of Tolerability and Safety of CBT101, an Autologous Natural Killer Cell, in Patients With Solid CancerCompletedNCT04557306Phase 1
• Ponatinib Plus Reduced-intensity Chemotherapy in the First-line Treatment of Adult Patients With Ph+ ALLTerminatedNCT04554459Phase 2
• Almonertinib as Upfront Treatment for Uncommon EGFR Mutation Harboring Non-Small-Cell Lung Cancer Patients: A Multicenter, Open-Label, Phase II TrialStatus unknownNCT04553887Phase 2
• A Study of JNJ-64251330 in Healthy ParticipantsCompletedNCT04552197Phase 1
• CRAFT: The NCT-PMO-1602 Phase II TrialCompletedNCT04551521Phase 2
• Neoadjuvant Study of Targeting ROS1 in Combination With Endocrine Therapy in Invasive Lobular Carcinoma of the Breast (ROSALINE)Active, not recruitingNCT04551495Phase 2
• Cabozantinib Combined With PD-1 and CTLA-4 Inhibition in Metastatic Soft Tissue SarcomaActive, not recruitingNCT04551430Phase 2
• Use Of A Response-Adapted Ruxolitinib-Containing Regimen For The Treatment Of Hemophagocytic LymphohistiocytosisActive, not recruitingNCT04551131Phase 1/2
• Pembrolizumab in Combination With Lenvatinib in Patients With Advanced Biliary Tract CarcinomaCompletedNCT04550624Phase 2
• Bioequivalence Study of Bosutinib Pediatric Capsule Relative to Commercial Tablet Under Fed ConditionCompletedNCT04549480Phase 1
• Camrelizumab Combined With Apatinib in Patients With PD-1 Antagonists Resistant Recurrent/Metastatic Nasopharyngeal CarcinomaStatus unknownNCT04548271Phase 2
• Anlotinib Combined With Dose-dense Temozolomide for the First Recurrent or Progressive Glioblastoma After STUPP RegimenStatus unknownNCT04547855Phase 2
• Camrelizumab Combined With Apatinib in Patients With First-line Platinum-resistant Recurrent/Metastatic Nasopharyngeal CarcinomaStatus unknownNCT04547088Phase 2
• Acalabrutinib in Combination With R-CHOP for Previously Untreated Diffuse Large B-cell Lymphoma (DLBCL)Active, not recruitingNCT04546620Phase 2
• Osimertinib and Abemaciclib in EGFR Mutant Non-Small Cell Lung Cancer After Osimertinib ResistanceActive, not recruitingNCT04545710Phase 2
• A Study of Combination Therapy in NSCLCStatus unknownNCT04544644Phase 2
• A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Ocrelizumab in Adult Participants With Primary Progressive Multiple SclerosisActive, not recruitingNCT04544449Phase 3
• Temodar Plus Tyrosine Kinase Inhibitors for Progressive CNS DiseaseCompletedNCT04541407Phase 1
• A Study to Evaluate the Drug Levels of BMS-986165 When Taken as Various Solid Tablet Prototypes by Healthy ParticipantsCompletedNCT04536961Phase 1
• Regorafenib in Combination With Metronomic Chemotherapies, and Low-dose Aspirin in Metastatic Colorectal CancerCompletedNCT04534218Phase 2
• A Biomarker-implemented Clinical Study Evaluating Mutations in MET and TP53 in a Population of Treatment-refractory Squamous Cell CarcinomaStatus unknownNCT04533321Phase 2
• A Drug-Drug Interaction Study to Evaluate the Effect of Ripretinib on the Pharmacokinetics of a CYP2C8 Probe Substrate in Patients with Advanced GISTCompletedNCT04530981Phase 1
• A Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL (ACE-LY-312)Active, not recruitingNCT04529772Phase 3
• Study of the Safety and Efficacy of STI-5656 (Abivertinib Maleate) in Subjects Hospitalized Due to COVID-19CompletedNCT04528667Phase 2
• REFOCUS: A First-in-Human Study of Highly Selective FGFR2 Inhibitor, RLY-4008, in Patients With ICC and Other Advanced Solid TumorsCompletedNCT04526106Phase 1/2
• Toripalimab Combined With Surufatinib for Locally Advanced Thyroid Cancer: a Phase II StudyStatus unknownNCT04524884Phase 2
• A Trial of Cabozantinib in Patients With Advanced, Low Proliferative NEN G3Active, not recruitingNCT04524208Phase 2
• Dose Escalation Study of Cabozantinib for Advanced HCC Patients with Preserved Liver FunctionCompletedNCT04522908Phase 2
• PRECISE CURATE.AI Pilot Clinical TrialStatus unknownNCT04522284Phase 1/2
• Camrelizumab Combined With Apatinib Mesylate for Perioperative Treatment of Resectable Hepatocellular CarcinomaActive, not recruitingNCT04521153Phase 2/3
• Open Label Two-Arm Study to Evaluate Rilzabrutinib in IgG4-Related Disease ParticipantsCompletedNCT04520451Phase 2
• A Single Arm, Phase Ib/II Trial of Single Agent Pacritinib in Patients With 1q21.3 Amplified Solid Tumors Enriching for Interleukin-1 Receptor-associated Kinase 1 Pathway Activation (PAIR)Active, not recruitingNCT04520269Phase 1/2
• Efficacy of SRT as Salvage Therapy in Patients With Brain Oligo-progression of EGFR-mutant Non-small Cell Lung Cancer After Failure of the Third-generation EGFR-TKIsStatus unknownNCT04519983Phase 2
• TP-0903 for the Treatment of FLT3 Mutated Acute Myeloid LeukemiaCompletedNCT04518345Early Phase 1
• Study of Sitravatinib, Nivolumab and Ipilimumab in Advanced or Metastatic Clear-Cell Renal Cell Carcinoma or Other Solid MalignanciesCompletedNCT04518046Phase 1
• A Phase 2 Trial of Fluzoparib Combined With Apatinib Versus Fluzoparib Monotherapy in Treatment With Relapsed Ovarian Cancer PatientsCompletedNCT04517357Phase 2
• Study to Assess the Effect of Branebrutinib on the Drug Levels of Rosuvastatin in Healthy ParticipantsCompletedNCT04515628Phase 1
• Sequential Regimen of Bendamustine Followed by Obinutuzumab (GA101), Zanubrutinib (BGB-3111) and Venetoclax (ABT-199) in Patients With Relapsed/Refractory CLLActive, not recruitingNCT04515238Phase 2
• Ibrutinib With Methotrexate and Temozolomide for Patients With Newly Diagnosed Primary CNS LymphomaStatus unknownNCT04514393Phase 2
• TOPAZ: Tucatinib in COmbination With Pembrolizumab And TrastuZumab in Patients With HER2-Positive Breast Cancer Brain MetastasesWithdrawnNCT04512261Phase 1/2
• Cabozantinib for Patients with Hepatocellular Carcinoma (HCC) Refractory to First Line TreatmentCompletedNCT04511455Phase 2
• Olmutinib 600 mg QD in Patients With T790M-positive NSCLC After Treatment With an EGFR-TKITerminatedNCT04510415Phase 1
• Rollover Study to Provide Continued Treatment for Participants With B-Cell Malignancies Previously Enrolled in Studies of Parsaclisib (INCB050465)Active, not recruitingNCT04509700Phase 2
• Treating Locally Advanced Head and Neck Malignant Tumor With Anlotinib and ChemoradiotherapyStatus unknownNCT04507035Phase 4
• Acalabrutinib and Obinutuzumab for the Treatment of Chronic Lymphocytic LeukemiaActive, not recruitingNCT04505254Phase 2
• Dacomitinib in Lung Cancer With Uncommon EGFR MutationsActive, not recruitingNCT04504071Phase 2
• Efficacy and Safety of Anlotinib Hydrochloride Combined With Nivolumab in the Treatment of Gastric and Esophageal CancerStatus unknownNCT04503967Phase 2
• Neoadjuvant Regorafenib in Combination With Nivolumab and Short-course Radiotherapy in Stage II-III Rectal CancerActive, not recruitingNCT04503694Phase 2
• Niraparib and Neratinib in Advanced Solid Tumors With Expansion Cohort in Advanced Ovarian CancerActive, not recruitingNCT04502602Phase 1
• Almonertinib Plus Chemotherapy as First-line Treatment in Patients With EGFR Concomitant Tumor Suppressor Gene MutationStatus unknownNCT04500717Phase 3
• Almonertinib Plus Chemotherapy as First-line Treatment in Patients With EGFR Concomitant Non-EGFR Driver Gene Mutant, Locally Advanced or Metastatic NSCLCStatus unknownNCT04500704Phase 3
• Phase 2 Trial of Afatinib Plus Prednisone for Advanced Squamous NSCLCActive, not recruitingNCT04497584Phase 2
• A Drug-drug Interaction Trial to Evaluate the Pharmacokinetics Effect of Rifampicin on FamitinibCompletedNCT04494659Phase 1
• A Study to Determine the Metabolism and Elimination of [14C]E7090 in Healthy Male ParticipantsCompletedNCT04493255Phase 1
• Azacitidine and Quizartinib for the Treatment of Myelodysplastic Syndrome or Myelodysplastic/Myeloproliferative Neoplasm With FLT3 or CBL MutationsActive, not recruitingNCT04493138Phase 1/2
• TACE Combined With Lenvatinib for Unresectable Hepatocellular CarcinomaStatus unknownNCT04490694Phase 2
• A Study to Evaluate Effects of Proton-pump Inhibitor on Acalabrutinib Capsule When Administered Orally With COCA-COLA in Healthy ParticipantsCompletedNCT04489797Phase 1
• I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill PatientsActive, not recruitingNCT04488081Phase 2
• A Phase II Clinical Trial of Cediranib and Olaparib Maintenance in Advanced Recurrent Cervical CancerActive, not recruitingNCT04487587Phase 2
• Trial of ZN-A-1041 Enteric Capsules in Patients With HER2-Positive Advanced Solid TumorsCompletedNCT04487236Phase 1
• Pyrotinib Maleate, CDK4/6 Inhibitor and Letrozole in Combination for Stage II-III TPBC: a Phase II TrialActive, not recruitingNCT04486911Phase 2
• Capability of Tofacitinib or Etanercept to Accelerate Tapering of NSAID and Treat-to-target Guided De-escalation of Corticosteroids in RA PatientsCompletedNCT04485325Phase 4
• Modified Immune Cells (CD19 CAR T Cells) and Acalabrutinib for the Treatment of Relapsed or Refractory Mantle Cell LymphomaActive, not recruitingNCT04484012Phase 2
• Study to Evaluate the Efficacy and Safety of Filgotinib in Participants With Active Ankylosing Spondylitis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drug TherapyWithdrawnNCT04483700Phase 3
• Study to Evaluate the Efficacy and Safety of Filgotinib in Participants With Active Ankylosing Spondylitis Who Have an Inadequate Response to Biologic Disease-Modifying Antirheumatic Drug TherapyWithdrawnNCT04483687Phase 3
• A Study to Evaluate the Efficacy and Safety of SHR0302 in Patients With Ankylosing SpondylitisCompletedNCT04481139Phase 2/3
• A Trial of Famitinib in Patients With Failure of First-Line Treatment For Intrahepatic CholangiocarcinomaWithdrawnNCT04479904Phase 2
• Effect of Itraconazole on the Pharmacokinetics of Pyrotinib in Healthy SubjectsCompletedNCT04479891Phase 1
• Ruxolitinib for Acute Respiratory Disorder Syndrome Due to COVID-19TerminatedNCT04477993Phase 2/3
• Cabozantinib and Abiraterone With Checkpoint Inhibitor Immunotherapy in Metastatic Hormone Sensitive Prostate Cancer (CABIOS Trial)CompletedNCT04477512Phase 1
• A Study of CG-806 in Patients With Relapsed or Refractory AML or Higher-Risk MDSTerminatedNCT04477291Phase 1
• PhaseⅠStudy of the HS-10241 in Patients With Advanced Solid TumorsStatus unknownNCT04477057Phase 1
• Camrelizumab in Combination With Apatinib in Refractory and Relapsed DLBCLStatus unknownNCT04476459Phase 1/2
• Optimization for Regorafenib in HCCTerminatedNCT04476329Phase 2
• Ponatinib in Adult Ph+ ALL Patients With MRD Positivity or Hematological RelapseActive, not recruitingNCT04475731Phase 2
• Neoadjuvant Afatinib Combination With Chemotherapy for Stage Ⅱa-Ⅲb NSCLC With EGFR Activating MutationStatus unknownNCT04470076Phase 2
• Tofacitinib in Hospitalized Patients With COVID-19 PneumoniaCompletedNCT04469114Phase 3
• Study of Oral Navitoclax Tablet in Combination With Oral Ruxolitinib Tablet Versus Best Available Therapy to Assess Change in Spleen Volume in Adult Participants With Relapsed/Refractory MyelofibrosisActive, not recruitingNCT04468984Phase 3
• Tofacitinib Citrate Topical Gel 3.2% FDA BA Bridging StudyCompletedNCT04468425Phase 1
• Tofacitinib Versus Methotrexate as the First Line DMARD in the Treatment of Rheumatoid ArthritisStatus unknownNCT04464642Phase 4

← Tyrosine Kinase Inhibitors overview